New drug combo shows promise for rare breast cancer
NCT ID NCT03620643
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, crizotinib and fulvestrant, in 33 people with advanced lobular breast cancer that had lost a protein called E-cadherin. It also tested crizotinib alone in people with diffuse gastric cancer, triple-negative lobular breast cancer, or other tumors with a CDH1 gene mutation. The main goal was to see if the treatment could shrink tumors and to check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CDH1 GENE MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
-
Guys and St Thomas NHS Foundation Trust
London, United Kingdom
-
Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
The Christie NHS Foundation Trust
Manchester, United Kingdom
-
University College London Hospital
London, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can surgery for stomach or esophageal cancer cloud the mind?